MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2016 International Congress

    Longterm outcome of cognition following subthalamic deep brain stimulation in Parkinson´s disease

    D. Gruber, C. Lisa, A. Kuehn, U. Kopp, G.H. Schneider, A. Kupsch (Beelitz-Heilstätten, Germany)

    Objective: Longterm, “real-life” assessment of cognitive evolution following subthalamic (STN) deep brain stimulation (DBS) in patients suffering from Parkinson´s disease. Background: Anecdotal reports have speculated…
  • 2016 International Congress

    Impaired cube copy on the MOCA indicates worse performance in several cognitive domains in Parkinson´s disease

    C. Gasca-Salas, M. Cohn, J.A. Pineda, J.A. Obeso (Madrid, Spain)

    Objective: We aimed to identify if an impairment of the cube copy of the Montreal Cognitive assessment (MoCA) was associated with worse cognitive status in…
  • 2016 International Congress

    Viewer responses to a virtual reality simulation of Parkinson’s disease psychosis

    J.G. Goldman, G.T. Stebbins, D. Fredericks, M. Upchurch (Chicago, IL, USA)

    Objective: To examine the accuracy, effectiveness, and utility of a novel virtual reality (VR) simulation representing symptoms of Parkinson's disease psychosis (PDP). Background: Diagnosing PDP…
  • 2016 International Congress

    GAITRite comparison between Parkinson’s disease stages

    W. Deeb, D. Martinez-Ramirez, J. Giugni, M. Okun, C. Hass (Gainesville, FL, USA)

    Objective: To compare gait performance across Parkinson's disease stages. Background: Parkinson's disease (PD) is characterized with changes in locomotion and posture, which are associated with…
  • 2016 International Congress

    Gender and age-based differential item functioning (DIF) analysis of MDS-UPDRS

    C.G. Goetz, L. Wang, G.T. Stebbins, B.C. Tilley, S. Luo (Chicago, IL, USA)

    Objective: Test if DIF due to gender or age is present in MDS-UPDRS items. Background: Testing a rating scale for DIF is a core step…
  • 2016 International Congress

    Home care program for patients with Parkinson’s disease – A Singapore experience

    H.L. Ng, W. Li, S. Abdul Karim, K.Y. Tay, W.L. Au, L.C.S. Tan (Singapore, Singapore)

    Objective: To review the disease profile of patients who were enrolled in the Home Care Program and evaluate the outcomes of the program. Background: With…
  • 2016 International Congress

    Successful treatment of movement disorders after resection of midbrain cavernous malformations: Report of two cases

    A. Smolanka, V. Smolanka, K. Karpinska, M. Dovhanych, T. Havryliv (Uzhhorod, Ukraine)

    Objective: To evaluate the treatment of movement disorders which presented as a consequence of haemorrhage from midbrain cavernous malformations. Background: Few cases of movement disorders…
  • 2016 International Congress

    Engrailed enhances dopamine synthesis in healthy dopaminergic neurons

    D. Alvarez-Fischer, M. Baaske, F. Vulinovic, J. Fuchs, P. Seibler, A. Rakovic, A. Prochiantz, C. Klein (Lübeck, Germany)

    Objective: The aim of the present study was to further elucidate the role of Engrailed in dopamine neurotransmission. Background: Engrailed1 and Engrailed2, collectively Engrailed, are…
  • 2016 International Congress

    Computational assessment of calcium channel effects on subthalamic nucleus neuronal cells: Study of abnormal bursting patterns in Parkinson’s disease

    C. Mahapatra, R. Manchanda (Mumbai, India)

    Objective: Understanding the drug effects with respect to various ion channels on subthalamic nucleus (STN) cells is the key to safety pharmacology assessment. Here our…
  • 2016 International Congress

    Effects of nilotinib on safety in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

    F. Pagan, E. Valadez, Y. Torres-Yaghi, R. Falconer, R. Mills, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)

    Objective: Nilotinib is FDA-approved for the treatment of chronic myeloid leukemia (CML) at 800mg oral dose twice daily. We examined the effects of lower doses…
  • « Previous Page
  • 1
  • …
  • 354
  • 355
  • 356
  • 357
  • 358
  • …
  • 425
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley